Trial is the first to show improved efficacy and a manageable safety profile after cCRT in unresectable locally advanced stage III NSCLC regardless of PD-L1 status. Read more
Dr. Benjamin C. Creelan shares his passion for cell therapy research and insights into current data. Read more
The benefits of early palliative care have been proven. Could negative connotations of palliative care be impeding its adoption? Read more
The speed at which a tumor progresses may prove to be a useful tool in therapeutic decision-making. Read more
Growing treatment options for patients with late-stage lung cancer bring hope—and challenges. Read more
Inaccurate health information can have grave consequences, but there are techniques providers can use to combat it. Read more
The strategy likely will not be pursued, however studies of PARP inhibitors plus immune checkpoint inhibitors are already in advanced stages. Read more
Interim analysis from ORIENT-31 demonstrates a four-drug regimen may be a reasonable option for patients whose disease has progressed on EGFR TKIs. Read more
Finding precision treatments after molecular testing requires a tool for reviewing actionable mutations. Read more
Without validated biomarkers for anti-angiogenesis therapy, VEGF inhibitors are increasingly being investigated. Read more